menu
    • menu
    [{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"ABMRF","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"ANS-858","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Amygdala Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amygdala Neurosciences \/ ABMRF","highestDevelopmentStatusID":"4","companyTruncated":"Amygdala Neurosciences \/ ABMRF"},{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"ANS-858","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Amygdala Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amygdala Neurosciences \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"4","companyTruncated":"Amygdala Neurosciences \/ National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ANS-858","moa":"ALDH2","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Amygdala Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amygdala Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Amygdala Neurosciences \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Amygdala Neurosciences

    Menu

    Amygdala Neurosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amygdala Neurosciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Amygdala Neurosciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANS-858

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amygdala Picks ANS-858 for Clinical use as ALDH2 Inhibitor

                            Details : ANS-858 is a new, proprietary, small molecule inhibitor of aldehyde dehydrogenase 2 (ALDH2). It is being evaluated for the treatment of substance use disorder.

                            Product Name : ANS-858

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 02, 2025

                            Lead Product(s) : ANS-858

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amygdala Neurosciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Amygdala Neurosciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANS-858

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : ABMRF

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder

                            Details : The financing aims to fund the clinical development of the company-lead product ANS-858, which is investigating in the early-stage clinical trial for alcohol use disorder.

                            Product Name : ANS-858

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 14, 2024

                            Lead Product(s) : ANS-858

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : ABMRF

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amygdala Neurosciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Amygdala Neurosciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANS-858

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : National Institute on Alcohol Abuse and Alcoholism

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Amygdala Neurosciences Awarded $2.0 Million NIH Grant to Conduct IND Enabling Studies

                            Details : The funding will support the IND-enabling and early-stage development of selective, reversible, orally bioavailable ALDH2 inhibitor ANS-858 to treat alcohol use disorder.

                            Product Name : ANS-858

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 08, 2023

                            Lead Product(s) : ANS-858

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : National Institute on Alcohol Abuse and Alcoholism

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth